Join our newsletter

Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM

APILAM informs you that the personal data that you provide to us by filling in this form will be treated by APILAM as responsible for this web. The purpose of the collection and processing of personal data that we request is to manage the registration of this subscription and send periodic bulletins with information and prospective offer of products or services.

Legitimation: Consent of the interested party

As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).

The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.

You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.

You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.

Last update Dec. 24, 2021

ثييثيلبيرازين

High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

Antihistamínico de 1ª generación, derivado de la fenotiazina con efecto sedante. Antipsicóico atípico de estrutura similar a la clozapina con efecto antidopaminérgico. Usado como antiemetico en procesos quirúrgicos y oncológicos y en el contol de vértigo y mareos. Adminsitración oral, rectal o intramuscular.

A fecha de última actualización no encontramos datos publicados sobre su excreción en leche materna.

Otros derivados de la fenotiazina se excretan mínimamente en leche, por lo que el uso puntual de la tietilperazina sería compatible con la lactancia.^{(LactMed, acceso en 12/2021)}

Las fenotiazinas pueden producir hiperprolactinema, aumento de la producción de leche y galatorrea. ^{(Goodnick 2002, Turkington 1972)}

Producto con escasas referencias bibliográficas y retirado del comercio en muhcos países.

Alternatives

Cinnarizine (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)
Meclozine Hydrochloride (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)
Ondansetron ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
Perphenazine ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
Sulpiride (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Very Low Risk

High Risk

Very High Risk

Very Low Risk

High Risk

Very High Risk

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Group

ثييثيلبيرازين belongs to this group or family:

ATC R06A: Antihistamines for systemic use.

Tradenames

Main tradenames from several countries containing ثييثيلبيرازين in its composition:

Torecan™

Pharmacokinetics

Variable	Value	Unit
Molecular weight	632	daltons
Protein Binding	60	%

References

Goodnick PJ, Rodriguez L, Santana O. Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother. 2002 Oct;3(10):1381-91. Review. Abstract
Turkington RW. Prolactin secretion in patients treated with various drugs: phenothiazines, tricyclic antidepressants, reserpine, and methyldopa. Arch Intern Med. 1972 Abstract

ثييثيلبيرازين

High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

Alternatives

Other names

Group

Tradenames

Pharmacokinetics

References

Total visits

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?